Search

Your search keyword '"Alford, John"' showing total 1,308 results
Start Over Author "Alford, John"
1,308 results on '"Alford, John"'

13. Conclusion

Author

Hibbing, John R., primary, Smith, Kevin B., additional, and Alford, John R., additional

Published
2024
Full Text
View/download PDF

15. Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia

Author

Boel, Judith A, de Bie, Rob MA, Schmand, Ben A, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, Bernard, Bryan, Stebbins, Glenn, Filoteo, J Vincent, Weintraub, Daniel, Caviness, John N, Belden, Christine, Zabetian, Cyrus P, Cholerton, Brenna A, Huang, Xuemei, Eslinger, Paul J, Leverenz, James B, Duff‐Canning, Sarah, Farrer, Matt, Anderson, Tim J, Myall, Daniel J, Naismith, Sharon L, Lewis, Simon JG, Halliday, Glenda M, Wu, Ruey‐Meei, Williams‐Gray, Caroline H, Breen, David P, Barker, Roger A, Yarnall, Alison J, Klein, Martin, Mollenhauer, Brit, Trenkwalder, Claudia, Kulisevsky, Jaime, Pagonabarraga, Javier, Gasca‐Salas, Carmen, Rodriguez‐Oroz, Maria C, Junque, Carme, Segura, Barbara, Barone, Paolo, Santangelo, Gabriella, Cammisuli, Davide M, Biundo, Roberta, Antonini, Angelo, Weis, Luca, Pedersen, Kenn Freddy, and Alves, Guido

Subjects
Acquired Cognitive Impairment, Neurodegenerative, Neurosciences, Parkinson's Disease, Dementia, Clinical Research, Aging, Brain Disorders, Neurological, dementia, mild cognitive impairment, global cognitive tests, Parkinson's disease, diagnostic accuracy, MDS Study Group Mild Cognitive Impairment in Parkinson's Disease
Abstract

BackgroundThe criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.MethodsThe MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.ResultsPD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P =

Published
2022

18. Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Author

Schröder, Martin, Renatus, Martin, Liang, Xiaoyou, Meili, Fabian, Zoller, Thomas, Ferrand, Sandrine, Gauter, Francois, Li, Xiaoyan, Sigoillot, Frederic, Gleim, Scott, Stachyra, Therese-Marie, Thomas, Jason R., Begue, Damien, Khoshouei, Maryam, Lefeuvre, Peggy, Andraos-Rey, Rita, Chung, BoYee, Ma, Renate, Pinch, Benika, Hofmann, Andreas, Schirle, Markus, Schmiedeberg, Niko, Imbach, Patricia, Gorses, Delphine, Calkins, Keith, Bauer-Probst, Beatrice, Maschlej, Magdalena, Niederst, Matt, Maher, Rob, Henault, Martin, Alford, John, Ahrne, Erik, Tordella, Luca, Hollingworth, Greg, Thomä, Nicolas H., Vulpetti, Anna, Radimerski, Thomas, Holzer, Philipp, Carbonneau, Seth, and Thoma, Claudio R.

Published
2024
Full Text
View/download PDF

19. A worldwide study of white matter microstructural alterations in people living with Parkinson’s disease

Author

Owens-Walton, Conor, Nir, Talia M., Al-Bachari, Sarah, Ambrogi, Sonia, Anderson, Tim J., Aventurato, Ítalo Karmann, Cendes, Fernando, Chen, Yao-Liang, Ciullo, Valentina, Cook, Phil, Dalrymple-Alford, John C., Dirkx, Michiel F., Druzgal, Jason, Emsley, Hedley C. A., Guimarães, Rachel, Haroon, Hamied A., Helmich, Rick C., Hu, Michele T., Johansson, Martin E., Kim, Ho Bin, Klein, Johannes C., Laansma, Max, Lawrence, Katherine E., Lochner, Christine, Mackay, Clare, McMillan, Corey T., Melzer, Tracy R., Nabulsi, Leila, Newman, Ben, Opriessnig, Peter, Parkes, Laura M., Pellicano, Clelia, Piras, Fabrizio, Piras, Federica, Pirpamer, Lukas, Pitcher, Toni L., Poston, Kathleen L., Roos, Annerine, Silva, Lucas Scárdua, Schmidt, Reinhold, Schwingenschuh, Petra, Shahid-Besanti, Marian, Spalletta, Gianfranco, Stein, Dan J., Thomopoulos, Sophia I., Tosun, Duygu, Tsai, Chih-Chien, van den Heuvel, Odile A., van Heese, Eva, Vecchio, Daniela, Villalón-Reina, Julio E., Vriend, Chris, Wang, Jiun-Jie, Wu, Yih-Ru, Yasuda, Clarissa Lin, Thompson, Paul M., Jahanshad, Neda, and van der Werf, Ysbrand

Published
2024
Full Text
View/download PDF

20. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Author

Schröder, Martin, Renatus, Martin, Liang, Xiaoyou, Meili, Fabian, Zoller, Thomas, Ferrand, Sandrine, Gauter, Francois, Li, Xiaoyan, Sigoillot, Frederic, Gleim, Scott, Stachyra, Therese-Marie, Thomas, Jason R., Begue, Damien, Khoshouei, Maryam, Lefeuvre, Peggy, Andraos-Rey, Rita, Chung, BoYee, Ma, Renate, Pinch, Benika, Hofmann, Andreas, Schirle, Markus, Schmiedeberg, Niko, Imbach, Patricia, Gorses, Delphine, Calkins, Keith, Bauer-Probst, Beatrice, Maschlej, Magdalena, Niederst, Matt, Maher, Rob, Henault, Martin, Alford, John, Ahrne, Erik, Tordella, Luca, Hollingworth, Greg, Thomä, Nicolas H., Vulpetti, Anna, Radimerski, Thomas, Holzer, Philipp, Carbonneau, Seth, and Thoma, Claudio R.

Published
2024
Full Text
View/download PDF

22. Learning Interpretable Regularized Ordinal Models from 3D Mesh Data for Neurodegenerative Disease Staging

Author

for the ENIGMA consortium, Zhao, Yuji, Laansma, Max A., van Heese, Eva M., Owens-Walton, Conor, Parkes, Laura M., Debove, Ines, Rummel, Christian, Wiest, Roland, Cendes, Fernando, Guimaraes, Rachel, Yasuda, Clarissa Lin, Wang, Jiun-Jie, Anderson, Tim J., Dalrymple-Alford, John C., Melzer, Tracy R., Pitcher, Toni L., Schmidt, Reinhold, Schwingenschuh, Petra, Garraux, Gäetan, Rango, Mario, Squarcina, Letizia, Al-Bachari, Sarah, Emsley, Hedley C. A., Klein, Johannes C., Mackay, Clare E., Dirkx, Michiel F., Helmich, Rick, Assogna, Francesca, Piras, Fabrizio, Bright, Joanna K., Spalletta, Gianfranco, Poston, Kathleen, Lochner, Christine, McMillan, Corey T., Weintraub, Daniel, Druzgal, Jason, Newman, Benjamin, Van Den Heuvel, Odile A., Jahanshad, Neda, Thompson, Paul M., van der Werf, Ysbrand D., Gutman, Boris, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Abdulkadir, Ahmed, editor, Bathula, Deepti R., editor, Dvornek, Nicha C., editor, Habes, Mohamad, editor, Kia, Seyed Mostafa, editor, Kumar, Vinod, editor, and Wolfers, Thomas, editor

Published
2022
Full Text
View/download PDF

24. Risk of Parkinson's disease dementia related to level I MDS PD‐MCI

Author

Hoogland, Jeroen, Boel, Judith A, Bie, Rob MA, Schmand, Ben A, Geskus, Ronald B, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Weintraub, Daniel, Junque, Carmen, Pedersen, Kenn F, Mollenhauer, Brit, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, and Disease”, on behalf of the MDS Study Group Validation of Mild Cognitive Impairment in Parkinson

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Aging, Prevention, Acquired Cognitive Impairment, Dementia, Behavioral and Social Science, Clinical Research, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Brain Disorders, Parkinson's Disease, Alzheimer's Disease, Neurodegenerative, Neurological, Age Factors, Aged, Cognitive Dysfunction, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Risk Factors, Sex Factors, dementia, mild cognitive impairment, neuropsychological tests, Parkinson's disease, survival analysis, MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”, Human Movement and Sports Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundThe International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.MethodsWe analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.ResultsLevel I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.ConclusionsLevel I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society.

Published
2019

25. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

Author

Hoogland, Jeroen, van Wanrooij, Lennard L, Boel, Judith A, Goldman, Jennifer G, Stebbins, Glenn T, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Junque, Carme, Pedersen, Kenn F, Mollenhauer, Brit, Zabetian, Cyrus P, Eslinger, Paul J, Lewis, Simon JG, Wu, Ruey‐Meei, Klein, Martin, Rodriguez‐Oroz, Maria C, Cammisuli, Davide M, Barone, Paolo, Biundo, Roberta, de Bie, Rob MA, Schmand, Ben A, Tröster, Alexander I, Burn, David J, Litvan, Irene, Filoteo, J Vincent, Geurtsen, Gert J, Weintraub, Daniel, and Disease”, on behalf of the IPMDS Study Group Validation of Mild Cognitive Impairment in Parkinson

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Mental Health, Behavioral and Social Science, Dementia, Neurodegenerative, Acquired Cognitive Impairment, Aging, Clinical Research, Parkinson's Disease, Neurological, Aged, Cognitive Dysfunction, Databases, Bibliographic, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Parkinson disease, MCI, mild cognitive impairment, cognition, neuropsychological, IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”, Human Movement and Sports Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

BackgroundNumerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.MethodsData from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data.ResultsPooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results.ConclusionsNormed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society.

Published
2018

28. Predisposed

Author

Hibbing, John R., primary, Smith, Kevin B., additional, and Alford, John R., additional

Published
2024
Full Text
View/download PDF

29. A Worldwide Study of White Matter Microstructural Alterations in People Living with Parkinson’s Disease

Author

Owens-Walton, Conor, primary, Nir, Talia M., additional, Al-Bachari, Sarah, additional, Ambrogi, Sonia, additional, Anderson, Tim J., additional, Aventurato, Ítalo Karmann, additional, Cendes, Fernando, additional, Chen, Yao-Liang, additional, Ciullo, Valentina, additional, Cook, Phil, additional, Dalrymple-Alford, John C., additional, Dirkx, Michiel F., additional, Druzgal, Jason, additional, Emsley, Hedley C. A., additional, Guimarães, Rachel, additional, Haroon, Hamied A., additional, Helmich, Rick C., additional, Hu, Michele T., additional, Johansson, Martin E., additional, Kim, Ho Bin, additional, Klein, Johannes C., additional, Laansma, Max, additional, Lawrence, Katherine E., additional, Lochner, Christine, additional, Mackay, Clare, additional, McMillan, Corey, additional, Melzer, Tracy R., additional, Nabulsi, Leila, additional, Newman, Ben, additional, Opriessnig, Peter, additional, Parkes, Laura M., additional, Pellicano, Clelia, additional, Piras, Fabrizio, additional, Piras, Federica, additional, Pirpamer, Lukas, additional, Pitcher, Toni L., additional, Poston, Kathleen L., additional, Roos, Annerine, additional, Silva, Lucas Scárdua, additional, Schmidt, Reinhold, additional, Schwingenschuh, Petra, additional, Shahid, Marian, additional, Spalletta, Gianfranco, additional, Stein, Dan J., additional, Thomopoulos, Sophia I., additional, Tosun, Duygu, additional, Tsai, Chih-Chien, additional, van den Heuvel, Odile A., additional, van Heese, Eva, additional, Vecchio, Daniela, additional, Villalón-Reina, Julio E., additional, Vriend, Chris, additional, Wang, Jiun-Jie, additional, Wu, Yih-Ru, additional, Yasuda, Clarissa Lin, additional, Thompson, Paul M., additional, Jahanshad, Neda, additional, and van der Werf, Ysbrand, additional

Published
2024
Full Text
View/download PDF

30. Investigating the association between white matter fiber density in the superior longitudinal fasciculus and inhibitory control in groups at‐risk of Alzheimer’s disease

Author

Tahara‐Eckl, Lenore T, primary, Roberts, Reece P, additional, Morgan, Catherine A, additional, Dell'Acqua, Flavio, additional, Kirk, Ian J, additional, Melzer, Tracy R, additional, Dalrymple‐Alford, John C, additional, Anderson, Tim J, additional, Cutfield, Nick J, additional, and Tippett, Lynette J, additional

Published
2023
Full Text
View/download PDF

33. Mild cognitive impairment as a risk factor for Parkinson's disease dementia

Author

Hoogland, Jeroen, Boel, Judith A, Bie, Rob MA, Geskus, Ronald B, Schmand, Ben A, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, and Disease”, on behalf of the MDS Study Group Validation of Mild Cognitive Impairment in Parkinson

Subjects
Aging, Behavioral and Social Science, Parkinson's Disease, Neurosciences, Rehabilitation, Neurodegenerative, Brain Disorders, Acquired Cognitive Impairment, Clinical Research, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Alzheimer's Disease, Dementia, 2.1 Biological and endogenous factors, Aetiology, Neurological, Adult, Aged, Aged, 80 and over, Cognitive Dysfunction, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Severity of Illness Index, Parkinson's disease, mild cognitive impairment, dementia, neuropsychological tests, survival analyses, MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”, Clinical Sciences, Human Movement and Sports Sciences, Neurology & Neurosurgery
Abstract

BackgroundThe International Parkinson and Movement Disorder Society criteria for mild cognitive impairment in PD were recently formulated.ObjectivesThe aim of this international study was to evaluate the predictive validity of the comprehensive (level II) version of these criteria by assessment of their contribution to the hazard of PD dementia.MethodsIndividual patient data were selected from four separate studies on cognition in PD that provided information on demographics, motor examination, depression, neuropsychological examination suitable for application of level II criteria, and longitudinal follow-up for conversion to dementia. Survival analysis evaluated the predictive value of level II criteria for cognitive decline toward dementia as expressed by the relative hazard of dementia.ResultsA total of 467 patients were included. The analyses showed a clear contribution of impairment according to level II mild cognitive impairment criteria, age, and severity of PD motor symptoms to the hazard of dementia. There was a trend of increasing hazard of dementia with declining neuropsychological performance.ConclusionsThis is the first large international study evaluating the predictive validity of level II mild cognitive impairment criteria for PD. The results showed a clear and unique contribution of classification according to level II criteria to the hazard of PD dementia. This finding supports their predictive validity and shows that they contribute important new information on the hazard of dementia, beyond known demographic and PD-specific factors of influence. © 2017 International Parkinson and Movement Disorder Society.

Published
2017

35. Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.

Author

Aye, William W. T., Stark, Megan R., Horne, Kyla‐Louise, Livingston, Leslie, Grenfell, Sophie, Myall, Daniel J., Pitcher, Toni L., Almuqbel, Mustafa M., Keenan, Ross J., Meissner, Wassilios G., Dalrymple‐Alford, John C., Anderson, Tim J., Heron, Campbell Le, and Melzer, Tracy R.

Subjects
PARKINSON'S disease, COGNITION disorders, POSITRON emission tomography, MAGNETIC resonance imaging, AMYLOID, MILD cognitive impairment
Abstract

INTRODUCTION: Recent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection ("early phase") reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid‐negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early‐phase 18F‐florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD. METHODS: One hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual‐phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cognitive performance and ASL MRI perfusion. RESULTS: Reduced eFBB uptake was associated with cognitive performance in brain regions previously linked to hypometabolism‐associated cognitive decline in PD, independent of amyloid status. Furthermore, eFBB uptake correlated with cerebral perfusion across widespread regions. DISCUSSION: EFBB uptake is a potential surrogate measure for cerebral perfusion/metabolism. A dual‐phase PET imaging approach may serve as a clinical tool for assessing cognitive impairment. Highlights: Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism.Parkinson's disease (PD) is a predominantly amyloid‐negative condition.Early‐phase florbetaben (eFBB) in PD was associated with cognitive performance.eFBB uptake reflects hypometabolism‐related cognitive decline in PD.eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion.eFBB distinguished dementia from normal cognition and mild cognitive impairment.Findings were independent of late‐phase Aβ burden.Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons

Author

Sanchez, Carlos G., Acker, Christopher M., Gray, Audrey, Varadarajan, Malini, Song, Cheng, Cochran, Nadire R., Paula, Steven, Lindeman, Alicia, An, Shaojian, McAllister, Gregory, Alford, John, Reece-Hoyes, John, Russ, Carsten, Craig, Lucas, Capre, Ketthsy, Doherty, Christian, Hoffman, Gregory R., Luchansky, Sarah J., Polydoro, Manuela, Dolmetsch, Ricardo, and Elwood, Fiona

Published
2021
Full Text
View/download PDF

41. Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Author

Cotton, Jennifer L., primary, Estrada Diez, Javier, primary, Sagar, Vivek, primary, Chen, Julie, primary, Piquet, Michelle, primary, Alford, John, primary, Song, Youngchul, primary, Li, Xiaoyan, primary, Riester, Markus, primary, DiMare, Matthew T., primary, Schumacher, Katja, primary, Boulay, Gaylor, primary, Sprouffske, Kathleen, primary, Fan, Lin, primary, Burks, Tyler, primary, Mansur, Leandra, primary, Wagner, Joel, primary, Bhang, Hyo-eun C., primary, Iartchouk, Oleg, primary, Reece-Hoyes, John, primary, Morris, Erick J., primary, Hammerman, Peter S., primary, Ruddy, David A., primary, Korn, Joshua M., primary, Engelman, Jeffrey A., primary, and Niederst, Matthew J., primary

Published
2023
Full Text
View/download PDF

42. Data from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Author

Cotton, Jennifer L., primary, Estrada Diez, Javier, primary, Sagar, Vivek, primary, Chen, Julie, primary, Piquet, Michelle, primary, Alford, John, primary, Song, Youngchul, primary, Li, Xiaoyan, primary, Riester, Markus, primary, DiMare, Matthew T., primary, Schumacher, Katja, primary, Boulay, Gaylor, primary, Sprouffske, Kathleen, primary, Fan, Lin, primary, Burks, Tyler, primary, Mansur, Leandra, primary, Wagner, Joel, primary, Bhang, Hyo-eun C., primary, Iartchouk, Oleg, primary, Reece-Hoyes, John, primary, Morris, Erick J., primary, Hammerman, Peter S., primary, Ruddy, David A., primary, Korn, Joshua M., primary, Engelman, Jeffrey A., primary, and Niederst, Matthew J., primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure and Table Legends from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Author

Cotton, Jennifer L., primary, Estrada Diez, Javier, primary, Sagar, Vivek, primary, Chen, Julie, primary, Piquet, Michelle, primary, Alford, John, primary, Song, Youngchul, primary, Li, Xiaoyan, primary, Riester, Markus, primary, DiMare, Matthew T., primary, Schumacher, Katja, primary, Boulay, Gaylor, primary, Sprouffske, Kathleen, primary, Fan, Lin, primary, Burks, Tyler, primary, Mansur, Leandra, primary, Wagner, Joel, primary, Bhang, Hyo-eun C., primary, Iartchouk, Oleg, primary, Reece-Hoyes, John, primary, Morris, Erick J., primary, Hammerman, Peter S., primary, Ruddy, David A., primary, Korn, Joshua M., primary, Engelman, Jeffrey A., primary, and Niederst, Matthew J., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

Author

Cotton, Jennifer L., primary, Estrada Diez, Javier, primary, Sagar, Vivek, primary, Chen, Julie, primary, Piquet, Michelle, primary, Alford, John, primary, Song, Youngchul, primary, Li, Xiaoyan, primary, Riester, Markus, primary, DiMare, Matthew T., primary, Schumacher, Katja, primary, Boulay, Gaylor, primary, Sprouffske, Kathleen, primary, Fan, Lin, primary, Burks, Tyler, primary, Mansur, Leandra, primary, Wagner, Joel, primary, Bhang, Hyo-eun C., primary, Iartchouk, Oleg, primary, Reece-Hoyes, John, primary, Morris, Erick J., primary, Hammerman, Peter S., primary, Ruddy, David A., primary, Korn, Joshua M., primary, Engelman, Jeffrey A., primary, and Niederst, Matthew J., primary

Published
2023
Full Text
View/download PDF

45. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Author

Adarmes-Gómez, Astrid D, Aguilar, Miquel, Aitkulova, Akbota, Akhmetzhanov, Vadim, Alcalay, Roy N, Alvarez, Ignacio, Alvarez, Victoria, Bandres-Ciga, Sara, Barrero, Francisco Javier, Bergareche Yarza, Jesús Alberto, Bernal-Bernal, Inmaculada, Billingsley, Kimberley, Blauwendraat, Cornelis, Blazquez, Marta, Bonilla-Toribio, Marta, Botía, Juan A, Boungiorno, María Teresa, Bras, Jose, Brice, Alexis, Brockmann, Kathrin, Bubb, Vivien, Buiza-Rueda, Dolores, Cámara, Ana, Carrillo, Fátima, Carrión-Claro, Mario, Cerdan, Debora, Chelban, Viorica, Clarimón, Jordi, Clarke, Carl, Compta, Yaroslau, Cookson, Mark R, Corvol, Jean-Christophe, Craig, David W, Danjou, Fabrice, Diez-Fairen, Monica, Dols-Icardo, Oriol, Duarte, Jacinto, Duran, Raquel, Escamilla-Sevilla, Francisco, Escott-Price, Valentina, Ezquerra, Mario, Faghri, Faraz, Feliz, Cici, Fernández, Manel, Fernández-Santiago, Rubén, Finkbeiner, Steven, Foltynie, Thomas, Gan-Or, Ziv, Garcia, Ciara, García-Ruiz, Pedro, Gasser, Thomas, Gibbs, J Raphael, Gomez Heredia, Maria Jose, Gómez-Garre, Pilar, González, Manuel Menéndez, Gonzalez-Aramburu, Isabel, Guelfi, Sebastian, Guerreiro, Rita, Hardy, John, Hassin-Baer, Sharon, Hernandez, Dena G, Heutink, Peter, Hoenicka, Janet, Holmans, Peter, Houlden, Henry, Infante, Jon, Iwaki, Hirotaka, Jesús, Silvia, Jimenez-Escrig, Adriano, Kaishybayeva, Gulnaz, Kaiyrzhanov, Rauan, Karimova, Altynay, Kia, Demis A, Kinghorn, Kerri J, Koks, Sulev, Krohn, Lynne, Kulisevsky, Jaime, Labrador-Espinosa, Miguel A, Leonard, Hampton L, Lesage, Suzanne, Lewis, Patrick, Lopez-Sendon, Jose Luis, Lovering, Ruth, Lubbe, Steven, Lungu, Codrin, Macias, Daniel, Majamaa, Kari, Manzoni, Claudia, Marín, Juan, Marinus, Johan, Marti, Maria Jose, Martinez, Maria, Martínez Torres, Irene, Martínez-Castrillo, Juan Carlos, Mata, Marina, Mencacci, Niccolo E, Méndez-del-Barrio, Carlota, Middlehurst, Ben, Mínguez, Adolfo, Mir, Pablo, Mok, Kin Y, Morris, Huw R, Muñoz, Esteban, Nalls, Mike A, Narendra, Derek, Noyce, Alastair J, Ojo, Oluwadamilola O, Okubadejo, Njideka U, Pagola, Ana Gorostidi, Pastor, Pau, Perez Errazquin, Francisco, Periñán-Tocino, Teresa, Pihlstrom, Lasse, Plun-Favreau, Helene, Quinn, John, R'Bibo, Lea, Reed, Xylena, Rezola, Elisabet Mondragon, Rizig, Mie, Rizzu, Patrizia, Robak, Laurie, Rodriguez, Antonio Sanchez, Rouleau, Guy A, Ruiz-Martínez, Javier, Ruz, Clara, Ryten, Mina, Sadykova, Dinara, Scholz, Sonja W, Schreglmann, Sebastian, Schulte, Claudia, Sharma, Manu, Shashkin, Chingiz, Shulman, Joshua M, Sierra, María, Siitonen, Ari, Simón-Sánchez, Javier, Singleton, Andrew B, Suarez-Sanmartin, Esther, Taba, Pille, Tabernero, Cesar, Tan, Manuela X, Tartari, Juan Pablo, Tejera-Parrado, Cristina, Toft, Mathias, Tolosa, Eduard, Trabzuni, Daniah, Valldeoriola, Francesc, van Hilten, Jacobus J, Van Keuren-Jensen, Kendall, Vargas-González, Laura, Vela, Lydia, Vives, Francisco, Williams, Nigel, Wood, Nicholas W, Zharkinbekova, Nazira, Zharmukhanov, Zharkyn, Zholdybayeva, Elena, Zimprich, Alexander, Ylikotila, Pauli, Shulman, Lisa M., von Coelln, Rainer, Reich, Stephen, Savitt, Joseph, Agee, Michelle, Alipanahi, Babak, Auton, Adam, Bell, Robert K., Bryc, Katarzyna, Elson, Sarah L., Fontanillas, Pierre, Furlotte, Nicholas A., Huber, Karen E., Hicks, Barry, Jewett, Ethan M., Jiang, Yunxuan, Kleinman, Aaron, Lin, Keng-Han, Litterman, Nadia K., McCreight, Jennifer C., McIntyre, Matthew H., McManus, Kimberly F., Mountain, Joanna L., Noblin, Elizabeth S., Northover, Carrie A.M., Pitts, Steven J., Poznik, G. David, Sathirapongsasuti, J. Fah, Shelton, Janie F., Shringarpure, Suyash, Tian, Chao, Tung, Joyce, Vacic, Vladimir, Wang, Xin, Wilson, Catherine H., Anderson, Tim, Bentley, Steven, Dalrymple-Alford, John, Fowdar, Javed, Gratten, Jacob, Halliday, Glenda, Henders, Anjali K., Hickie, Ian, Kassam, Irfahan, Kennedy, Martin, Kwok, John, Lewis, Simon, Mellick, George, Montgomery, Grant, Pearson, John, Pitcher, Toni, Sidorenko, Julia, Silburn, Peter A., Vallerga, Costanza L., Visscher, Peter M., Wallace, Leanne, Wray, Naomi R., Xue, Angli, Yang, Jian, Zhang, Futao, Vallerga, Costanza L, Heilbron, Karl, Chang, Diana, Tan, Manuela, Young, Emily, Pihlstrøm, Lasse, Leonard, Hampton, Botia, Juan A, Jankovic, Joseph, Shulman, Lisa M, Sutherland, Margaret, Tienari, Pentti, Andreassen, Ole A, Bangale, Tushar, Hinds, David A, Hardy, John A, Visscher, Peter M, and Graham, Robert R

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results